Filing Details
- Accession Number:
- 0001610717-24-000027
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-11 19:59:41
- Reporting Period:
- 2024-01-09
- Accepted Time:
- 2024-01-11 19:59:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1880438 | An2 Therapeutics Inc. | ANTX | Pharmaceutical Preparations (2834) | 820606654 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1916925 | Michael Kevin Krause | C/O An2 Therapeutics, Inc. 1800 El Camino Real, Suite D Menlo Park CA 94027 | Chief Strategy Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-09 | 2,417 | $0.42 | 4,331 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-01-09 | 5,000 | $6.60 | 9,331 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-09 | 7,417 | $20.14 | 1,914 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-01-09 | 2,417 | $0.00 | 2,417 | $0.42 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-01-09 | 5,000 | $0.00 | 5,000 | $6.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 49,868 | 2030-01-22 | No | 4 | M | Direct | |
| 26,832 | 2031-04-29 | No | 4 | M | Direct |
Footnotes
- The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.
- Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.33. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020 and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.
- The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.
Billionaire Hedge Funds
